Specificity of somatostatin receptor scintigraphy: A prospective study and effects of false-positive localizations on management in patients with gastrinomas

Journal of Nuclear Medicine

Volumn 40, Issue 4, 1999, Pages 539-553

  Gibril, Fathia ^b   Reynolds, James C ^b   Chen, Clara C ^b   Yu, Fang ^b   Goebel, Stephan U ^b   Serrano, Jose ^b   Doppman, John L ^b   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NONE

Author keywords

Gastroenteropancreatic tumors; Neuroendocrine tumor; Somatostatin receptor scintigraphy; Zollinger Ellison syndrome

Indexed keywords

SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; GASTRINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCINTIGRAPHY; TUMOR LOCALIZATION; ZOLLINGER ELLISON SYNDROME;

FALSE POSITIVE REACTIONS; FEMALE; GASTRINOMA; HUMANS; INDIUM RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; SODIUM PERTECHNETATE TC 99M; SOMATOSTATIN; TIME FACTORS; ZOLLINGER-ELLISON SYNDROME;

EID: 0032929935     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 1]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-711.
2. Jensen RT. Peptide therapy. Recent advances in the use of somatostatin and other peptide receptor agonists and antagonists. In: Lewis JH, Duhois A, eds. Current Clinical Topics in Gastrointestinal Pharmacology. Maiden, MA: Blackwell Science; 1997:144-223.
3. van Eijck CH, Lamberts SW, Lemaire LC, et al. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg. 1996;224:119-124.
4. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med. 1996;125:26-34.
5. Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997;38:853-858.
6. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome: results of a 10-year prospective study. Ann Surg. 1992;215:8-18.
7. Jensen RT, Gardner JD. Gastrinoma. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The Pancreas: Biology. Pathobiology and Disease. 2nd ed. New York, NY: Raven Press; 1993:931-978.
8. Gibril F, Doppman JL, Reynolds JC, et al. Bone metastases in patients with gastrinomas: a prospective study of hone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol. 1998;16:1040-1053.
9. Jensen RT. Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med. 1998;243:477-488.
10. Benya RV, Metz DC, Venzon DJ, et al. Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type 1. Am J Med. 1994;97:436-444.
11. Pisegna JR, Norton JA, Slimak GG, Metz DC, Maton PN, Jensen RT. Effects of curative resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology. 1992;102:767-778.
12. Metz DC, Jensen RT. Advances in gastric antisecretory therapy in Zollinger-Ellison syndrome. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Basel, Switzerland: S. Karger; 1995:240-257.
13. Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenteralogy. 1995;108:1637-1649.
14. Orbuch M, Doppman JL, Strader DB, et al. Imaging for pancreatic endocrine tumor localization: recent advances. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research, Basel, Switzerland: S. Karger; 1995:268-281.
15. Termanini B, Gibril F, Reynolds JC, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterelogy. 1997;112:335-347.
16. Termanini B, Gibril F, Doppman JL, et al. Distinguishing small hepatic hemangiomas from vascular liver metastases in patients with gastrinoma: use of a somatostatin-receptor scintigraphic agent. Radiology. 1997;202:151-158.
17. Alexander HR, Fraker DL, Norton JA, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg. 1998;228:228-238.
18. Gibril F, Curtis LT, Termanini B, et al. Primary cardiac gastrinoma causing Zollinger-Ellison syndrome. Gastroenterology. 1997;112:567-574.
19. 111In-octreotide. Nucl Med Commun. 1995;16:756-766.
20. Kwekkeboom DJ, van Urk H, Pauw BK, et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med. 1993;34:873-878.
21. Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med. 1994;21:1106-1113.
22. O'Brien JP. Somatostatin receptor-based imaging in malignant lymphomas. J Nucl Med. 1995;36:19-20.
23. van Eijck CH, Krenning EP, Bootsma A, et al. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet. 1994;343:640-643.
24. 1]-octreotide scintigraphy. Cancer Res. 1995;55: 5805s-5810s.
25. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 1994;79:1416-1423.
26. Vanhagen PM, Markusse HM, Lamberts SW, Kwekkeboom DJ, Reubi JC, Krenning EP. Somatostatin receptor imaging: the presence of somatostatin receptors in rheumatoid arthritis. Arthritis Rheum. 1994;37:1521-1527.
27. Kahaly G, Diaz M, Hahn K, Beyer J, Bockisch A. Indium-111-pentetreotide scintigraphy in Graves ophthalmopathy. J Nucl Med. 1995;36:550-554.
28. 111In octreotide scintigraphy in the evaluation of head and neck lesions. Am J Neuroradiol. 1997;18:1073-1080.
29. Lebtahi R, Cadiot G, Marmuse JP, et al. False-positive somatostatin receptor scintigraphy due to an accessory spleen. J Nucl Med. 1997;38:1979-1981.
30. Kipper MS, Krohn LD. Gallbladder visualization at twenty-four hours with octreotide scintigraphy. Potential false-positive finding. Clin Nucl Med. 1997;22: 253-254.
31. Krausz Y, Shibley N, De Jong RB, Yaffe S, Glaser B. Gallbladder visualization with In-111 labeled octreotide. Clin Nucl Med. 1994;19:133-135.
32. Garancini S, La Rosa S, De Palma D, Uccella S, Golonia F. Uptake of In-111 pentetreotide by normally functioning nodular goiters. Clin Nucl Med. 1997;22: 625-627.
33. Hoegerle S, Nitzsche EU, Stumpf A, et al. Incidental appendix carcinoid value of somatostatin receptor imaging. Clin Nucl Med. 1997;22:467-469.
34. Teh BT, McArdle J, Chan SP, et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine (Baltimore). 1997;76:21-29.
35. Lastoria S, Vergara E, Palmieri G, et al. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phel-octreotide scintigraphy. J Nucl Med. 1998; 39:634-639.
36. Dorr U, Wurstlin S, Frank-Raue K, et al. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study. Horm Metab Res. 1993;27(suppl):48-55.
37. Tenenbaum F, Lumbroso J, Schlumberger M, Caillou B, Fragu P, Parmentier C. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 1995;36:807-810.
38. Ozturk E, Gunalp B, Ozguven M, et al. The visualization of granulomatous disease with somatostatin receptor scintigraphy. Clin Nucl Med. 1994;19:129-132.
39. 111In-pentetreotide scan. Ann Oncol. 1998;9:213-216.
40. Joshi VV, Nord KS, Hanna M. Case 3. Renal gastrinoma with Zollinger-Ellison syndrome. Pediatr Pathol. 1986;6:475-476.